Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 8,247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Clear all
Completed Phase 4 Interventional Results available

Baclofen to Reduce Alcohol Use in Veterans With HCV

NCT01008280
View directory record Official record
Conditions
Hepatitis C, Alcohol Use Disorders
Interventions
baclofen, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Long Beach, California • San Diego, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Scavenging of Reactive Carbonyl Species by Soymilk in Humans

NCT07874360
View directory record Official record
Conditions
Human Health, Reactive Carbonyl Species, Polyphenols
Interventions
Soymilk, Control Group
Dietary Supplement
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
25 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

NCT06451159
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Biological · Drug
Lead sponsor
Bruce Cree
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

NCT01858376
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Capros dietary supplement
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 28, 2026, 10:09 AM EDT
Terminated Phase 1 Interventional

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

NCT00971191
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 28, 2026, 10:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

NCT07767474
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ATX-898, ATX-898, fulvestrant, ribociclib
Drug
Lead sponsor
Antares Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Fort Worth, Texas • Houston, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Influenza and Tdap Vaccination of Pregnant Women

NCT04444518
View directory record Official record
Conditions
Immunization; Infection, Pregnancy Related
Interventions
VAX-MOM Intervention, Standard of Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
12,760 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 28, 2026, 10:09 AM EDT
Completed No phase listed Observational

Patients' Perspectives on Identity, Ancestry and Genetics

NCT00359710
View directory record Official record
Conditions
Family History
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Dosing Schedules Study for HPV Vaccine

NCT00862810
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Received HPV vaccine first, Received concomitant vaccines first
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Cytochrome P450 4F Enzymes and Drug Interactions

NCT01250535
View directory record Official record
Conditions
Healthy Volunteers, Drug Drug Interactions
Interventions
Warfarin, Placebo, Lovastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 28, 2026, 10:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

NCT05636618
View directory record Official record
Conditions
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Interventions
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

NCT00125190
View directory record Official record
Conditions
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions
rhIGF-1 (mecasermin) for a period of 86 weeks
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 28, 2026, 10:09 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Growth and Tolerance Trial on Infant Formula With HMO

NCT04066413
View directory record Official record
Conditions
Healthy Growth
Interventions
Standard infant formula, Infant formula supplemented with HMO
Other
Lead sponsor
FrieslandCampina
Industry
Eligibility
Up to 1 Month
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

NCT01218113
View directory record Official record
Conditions
AIDS
Interventions
GSK Biologicals HIV Vaccine 732462, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Scavenging of Reactive Carbonyl Species by Blueberries in Humans

NCT07873723
View directory record Official record
Conditions
Human Health, Reactive Carbonyl Species, Polyphenols
Interventions
Blueberries, control group
Dietary Supplement
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
25 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

NCT00875979
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels

NCT00284011
View directory record Official record
Conditions
Heart Disease
Interventions
SAMe, Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)

NCT01802892
View directory record Official record
Conditions
Transplantation, Stem Cell
Interventions
Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

NCT04135937
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking
Interventions
Bupropion, Varenicline, Cognitive Behavioral Therapy, Nicotine Replacement Therapy, Relapse Prevention Text Messaging
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 28, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

NCT00987337
View directory record Official record
Conditions
Hepatitis, Hepatitis C
Interventions
Filibuvir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anaheim, California • Coronado, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 28, 2026, 10:09 AM EDT
Enrolling by invitation No phase listed Observational

Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)

NCT03895645
View directory record Official record
Conditions
Healthy Volunteer Samples
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 116 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 10:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

NCT00006445
View directory record Official record
Conditions
Down Syndrome, Chromosome Abnormalities
Interventions
Ultrasound, Serum screen
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
38,000 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2007 · Synced Oct 28, 2026, 10:09 AM EDT